Pazopanib

For research use only.

Catalog No.S3012 Synonyms: GW786034

41 publications

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pazopanib has been cited by 41 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell NWTRc5JlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHoNWhKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygbYM2OD1{Lki5[U0xPSEQvF2= M1HDeXNCVkeHUh?=
human AN3-CA cell NEDKXY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrnR4xKdmirYnn0bY9vKG:oIHj1cYFvKEGQMz3DRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjB3IH7N MXTTRW5ITVJ?
human CGTH-W-1 cell MoG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= NYG3e4N{W0GQR1XS
human GDM-1 cell MoG5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4X0TWlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFMvQTlibl2= MYDTRW5ITVJ?
human A204 cell M4TYbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmL3TY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P M{TOe3NCVkeHUh?=
human G-402 cell M13sdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7sSZJKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMyNjh2IH7N MWfTRW5ITVJ?
human MFE-296 cell NGT6W|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6ODJ{IN88US=> NVzSRo1JW0GQR1XS
human NOS-1 cell MkLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;MD62OVk5PyEQvF2= NXz1NWtZW0GQR1XS
human KG-1 cell Mo[zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkexO|U2KM7:TR?= NWj2WnJCW0GQR1XS
human HT55 cell M{jNb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhVPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4O|gyKM7:TR?= MYTTRW5ITVJ?
human MG-63 cell NGjibIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4S0S2lvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> NFnIdXVUSU6JRWK=
human CCF-STTG1 cell NHPQSIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5yNEm4NUDPxE1? MkPNV2FPT0WU
human RT-112 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFXPWFlKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTB|N{[g{txO MXjTRW5ITVJ?
human MC-IXC cell NH\hepNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfIfI9UUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFzNUGyJO69VQ>? MnHhV2FPT0WU
human HUTU-80 cell M3nXTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXYbJJKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ6MUCzJO69VQ>? NH\mclBUSU6JRWK=
human MV-4-11 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTDTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PDVyMTFOwG0> MUfTRW5ITVJ?
human LCLC-103H cell NW\rZ444T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MVzTRW5ITVJ?
human G-401 cell MoX6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnRTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFY1OjFizszN MUPTRW5ITVJ?
human A704 cell MkHkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml3PTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFMzOyEQvF2= NIrpZllUSU6JRWK=
human ESS-1 cell MkPYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjITWo3UW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO NGe2bVVUSU6JRWK=
human HLE cell NVHkU4tmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP MmG4V2FPT0WU
human NY cell MljCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfKTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP M2T1U3NCVkeHUh?=
human A427 cell M17aOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPq[ZRKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> NVny[odXW0GQR1XS
human SK-N-DZ cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzOzhzIN88US=> M2izW3NCVkeHUh?=
human J82 cell NHXyPVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\tVlg2UW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA3ODh6IN88US=> NY\lSZlEW0GQR1XS
human GI-1 cell M4X6bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXLJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyPVUyKM7:TR?= NHnFXGZUSU6JRWK=
human NCI-H716 cell NXrjblBWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXPEXWRMUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFcyPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwM{G2N|Mh|ryP NFLIbIlUSU6JRWK=
human SF126 cell NFy0O4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj60O|Q2QSEQvF2= MXvTRW5ITVJ?
human H4 cell M17yUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nHU2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxNlYzKM7:TR?= MXzTRW5ITVJ?
human LB831-BLC cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoLQTY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? NY\FU3l{W0GQR1XS
human HCC1395 cell MmS1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU5OTV4IN88US=> MYrTRW5ITVJ?
human LK-2 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfuVXhKdmirYnn0bY9vKG:oIHj1cYFvKEyNLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlY1PTZ7IN88US=> MVvTRW5ITVJ?
human G-361 cell NVW1Nm1qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYHmOmZrUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO MkTSV2FPT0WU
human NCI-H2342 cell NFO0XZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TpZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:Oy5zM{OxOkDPxE1? MVHTRW5ITVJ?
human SK-LU-1 cell  M1P0XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWfBdoVlUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? Ml;aV2FPT0WU
human IGROV-1 cell  MoHwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> Mn\2V2FPT0WU
human EB2 cell MnP2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP NGjrPXlUSU6JRWK=
human CAL-54 cell M{Tle2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN M2fSZnNCVkeHUh?=
human LB1047-RCC cell Mlf4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;UUnN7UW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjN|MUO2PEDPxE1? MorqV2FPT0WU
Daudi cell NFnSRZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGq0PGdKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWzNVY1KM7:TR?= NELRSphUSU6JRWK=
human Daudi cell MniwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= M13vR3NCVkeHUh?=
human A172 cell NIPGO4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\pbGlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|M4QSEQvF2= NYTwbnNMW0GQR1XS
human KGN cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIS4VpRKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFY4ODlizszN MVnTRW5ITVJ?
human SNG-M cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2fZO2lvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> Ml[0V2FPT0WU
human SW1710 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGHybnBKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDd|MUig{txO NWnhNm1nW0GQR1XS
human HT29 cells Mkn4VJJwdGmoZYLheIlwdiCjc4PhfS=> NHjYOJNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= MlzpNVg3OjB|OEK=
human A375P cells NFXicINRem:uaX\ldoF1cW:wIHHzd4F6 NGf5TJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|VRKGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt NXTjNW9mOTh4MkCzPFI>
human HN5 cells MlK2VJJwdGmoZYLheIlwdiCjc4PhfS=> NEXGUpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= M2PtOFE5PjJyM{iy
HUVEC NEHw[FFHfW6ldHnvckBie3OjeR?= NWnOcHh5OSEQvF2= NY\ueIgzPiCq MYjBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? MUGyOFA{PjB2Mh?=
human Daoy cell NEXJTZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\iTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63O|k1QSEQvF2= M4[wZnNCVkeHUh?=
human DMS-273 cell NFPvV|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPpNVJKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl4MkCyJO69VQ>? NUXuNHhuW0GQR1XS
human KU812 cell NVvSOGh5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmTGTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|c5OTJizszN M3TldnNCVkeHUh?=
human NCI-H727 cell MoThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2j0eWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjRyOUCxJO69VQ>? NHi2UmlUSU6JRWK=
human P30-OHK cell NGfqN49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoPUTY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41Pjl2IN88US=> NH\qdmxUSU6JRWK=
human MIA-PaCa-2 cell NWrKNmg6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZyNE[2JO69VQ>? NWHMNHlNW0GQR1XS
human TT cell M3j3UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKGi3bXHuJHRVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54NkK0JO69VQ>? MkOzV2FPT0WU
human DK-MG cell NVP0OYp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjzTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt MUnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034
Smiles CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT03091465 Completed -- Metastatic Renal Cell Carcinoma Spanish Oncology Genito-Urinary Group December 20 2016 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID